Masoprocol - TriAct Therapeutics

Drug Profile

Masoprocol - TriAct Therapeutics

Alternative Names: INS-18; INSM-18; Masoprocal; TT-100

Latest Information Update: 13 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Insmed
  • Developer Insmed; University of California at San Francisco
  • Class Anti-inflammatories; Catechols; Lignans; Small molecules
  • Mechanism of Action Epidermal growth factor receptor antagonists; Insulin-like growth factor I inhibitors; Protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Prostate cancer

Most Recent Events

  • 27 Jul 2016 No development reported - Phase-II for Prostate cancer in USA (PO)
  • 06 Mar 2014 Phase II development is ongoing in USA
  • 01 Jun 2011 University of California at San Francisco terminates a phase II trial in Prostate cancer in USA due to lack of efficacy (NCT00678015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top